248 related articles for article (PubMed ID: 33651140)
41. The role of transcriptional coactivator TAZ in gliomas.
Li W; Dong S; Wei W; Wang G; Zhang A; Pu P; Jia Z
Oncotarget; 2016 Dec; 7(50):82686-82699. PubMed ID: 27764783
[TBL] [Abstract][Full Text] [Related]
42. Metformin inhibits glioma cells stemness and epithelial-mesenchymal transition via regulating YAP activity.
Yuan X; Wei W; Bao Q; Chen H; Jin P; Jiang W
Biomed Pharmacother; 2018 Jun; 102():263-270. PubMed ID: 29567539
[TBL] [Abstract][Full Text] [Related]
43. Fluorescence polarization assay for the identification and evaluation of inhibitors at YAP-TEAD protein-protein interface 3.
Zhou W; Li Y; Song J; Li C
Anal Biochem; 2019 Dec; 586():113413. PubMed ID: 31479631
[TBL] [Abstract][Full Text] [Related]
44. Verteporfin targeting YAP1/TAZ-TEAD transcriptional activity inhibits the tumorigenic properties of gastric cancer stem cells.
Giraud J; Molina-Castro S; Seeneevassen L; Sifré E; Izotte J; Tiffon C; Staedel C; Boeuf H; Fernandez S; Barthelemy P; Megraud F; Lehours P; Dubus P; Varon C
Int J Cancer; 2020 Apr; 146(8):2255-2267. PubMed ID: 31489619
[TBL] [Abstract][Full Text] [Related]
45. ACYP2 contributes to malignant progression of glioma through promoting Ca
Li M; Ruan B; Wei J; Yang Q; Chen M; Ji M; Hou P
J Exp Clin Cancer Res; 2020 Jun; 39(1):106. PubMed ID: 32517717
[TBL] [Abstract][Full Text] [Related]
46. Structural and functional analysis of the YAP-binding domain of human TEAD2.
Tian W; Yu J; Tomchick DR; Pan D; Luo X
Proc Natl Acad Sci U S A; 2010 Apr; 107(16):7293-8. PubMed ID: 20368466
[TBL] [Abstract][Full Text] [Related]
47. The Hippo Pathway and YAP/TAZ-TEAD Protein-Protein Interaction as Targets for Regenerative Medicine and Cancer Treatment.
Santucci M; Vignudelli T; Ferrari S; Mor M; Scalvini L; Bolognesi ML; Uliassi E; Costi MP
J Med Chem; 2015 Jun; 58(12):4857-73. PubMed ID: 25719868
[TBL] [Abstract][Full Text] [Related]
48. Effects of small nucleolar RNA SNORD44 on the proliferation, apoptosis and invasion of glioma cells.
Xia XR; Li WC; Yu ZT; Li J; Peng CY; Jin L; Yuan GL
Histochem Cell Biol; 2020 Apr; 153(4):257-269. PubMed ID: 32062699
[TBL] [Abstract][Full Text] [Related]
49. Discovery of a cryptic site at the interface 2 of TEAD - Towards a new family of YAP/TAZ-TEAD inhibitors.
Sturbaut M; Bailly F; Coevoet M; Sileo P; Pugniere M; Liberelle M; Magnez R; Thuru X; Chartier-Harlin MC; Melnyk P; Gelin M; Allemand F; Guichou JF; Cotelle P
Eur J Med Chem; 2021 Dec; 226():113835. PubMed ID: 34509860
[TBL] [Abstract][Full Text] [Related]
50. MEIS2C and MEIS2D promote tumor progression via Wnt/β-catenin and hippo/YAP signaling in hepatocellular carcinoma.
Guan L; Li T; Ai N; Wang W; He B; Bai Y; Yu Z; Li M; Dong S; Zhu Q; Ding XX; Zhang S; Li M; Tang G; Xia X; Zhao J; Lin S; Yao S; Zhang L; Chen G; Liu FE; Li X; Zhang H
J Exp Clin Cancer Res; 2019 Oct; 38(1):417. PubMed ID: 31623651
[TBL] [Abstract][Full Text] [Related]
51. Dissection of the interaction between the intrinsically disordered YAP protein and the transcription factor TEAD.
Mesrouze Y; Bokhovchuk F; Meyerhofer M; Fontana P; Zimmermann C; Martin T; Delaunay C; Erdmann D; Schmelzle T; Chène P
Elife; 2017 Apr; 6():. PubMed ID: 28430104
[TBL] [Abstract][Full Text] [Related]
52. Identification of Small-molecule YAP-TEAD inhibitors by High-throughput docking for the Treatment of colorectal cancer.
Li L; Li R; Wang Y
Bioorg Chem; 2022 May; 122():105707. PubMed ID: 35247806
[TBL] [Abstract][Full Text] [Related]
53. Hypoxia induced ferritin light chain (FTL) promoted epithelia mesenchymal transition and chemoresistance of glioma.
Liu J; Gao L; Zhan N; Xu P; Yang J; Yuan F; Xu Y; Cai Q; Geng R; Chen Q
J Exp Clin Cancer Res; 2020 Jul; 39(1):137. PubMed ID: 32677981
[TBL] [Abstract][Full Text] [Related]
54. Structure-based derivation and optimization of YAP-like coactivator-derived peptides to selectively target TEAD family transcription factors by hydrocarbon stapling and cyclization.
He B; Wu T; He P; Lv F; Liu H
Chem Biol Drug Des; 2021 Jun; 97(6):1129-1136. PubMed ID: 33283479
[TBL] [Abstract][Full Text] [Related]
55. Effect of the acylation of TEAD4 on its interaction with co-activators YAP and TAZ.
Mesrouze Y; Meyerhofer M; Bokhovchuk F; Fontana P; Zimmermann C; Martin T; Delaunay C; Izaac A; Kallen J; Schmelzle T; Erdmann D; Chène P
Protein Sci; 2017 Dec; 26(12):2399-2409. PubMed ID: 28960584
[TBL] [Abstract][Full Text] [Related]
56. Identification of mechanism that couples multisite phosphorylation of Yes-associated protein (YAP) with transcriptional coactivation and regulation of apoptosis.
Lee KK; Yonehara S
J Biol Chem; 2012 Mar; 287(12):9568-78. PubMed ID: 22308035
[TBL] [Abstract][Full Text] [Related]
57. Verteporfin inhibits growth of human glioma in vitro without light activation.
Al-Moujahed A; Brodowska K; Stryjewski TP; Efstathiou NE; Vasilikos I; Cichy J; Miller JW; Gragoudas E; Vavvas DG
Sci Rep; 2017 Aug; 7(1):7602. PubMed ID: 28790340
[TBL] [Abstract][Full Text] [Related]
58. YAP-Dependent BiP Induction Is Involved in Nicotine-Mediated Oral Cancer Malignancy.
Chien CY; Chen YC; Hsu CC; Chou YT; Shiah SG; Liu SY; Hsieh AC; Yen CY; Lee CH; Shieh YS
Cells; 2021 Aug; 10(8):. PubMed ID: 34440849
[TBL] [Abstract][Full Text] [Related]
59. Nuclear actin regulates cell proliferation and migration via inhibition of SRF and TEAD.
McNeill MC; Wray J; Sala-Newby GB; Hindmarch CCT; Smith SA; Ebrahimighaei R; Newby AC; Bond M
Biochim Biophys Acta Mol Cell Res; 2020 Jul; 1867(7):118691. PubMed ID: 32119877
[TBL] [Abstract][Full Text] [Related]
60. MYC/NBS1-Mediated DNA Damage Response is Involved in the Inhibitory Effect of Hydroxysafflor Yellow A on Glioma Cells.
Tang D; Huang T; Tian Q; Wang J
Drug Des Devel Ther; 2021; 15():1749-1763. PubMed ID: 33953544
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
